Your Gout Flare Ended, but Your Heart Didn’t Get the Memo: The 2-Month Risk

Your big toe finally stops throating. The swelling goes down, you put a shoe on again, and you tell yourself the flare is over. It is, in the joint. But your blood vessels may not have gotten the message. A gout flare is not just a painful week for your foot. It is a short, body-wide inflammatory event, and in the weeks right after it, your risk of a heart attack or a stroke climbs sharply.

How sharply? In a study of more than 62,000 people with gout in England, the risk of a heart attack or stroke was about 1.9 times normal in the two months after a flare, still elevated through four months, and back to usual by six months. Researchers have since found the same pattern for dangerous blood clots and for new irregular heart rhythms, most often atrial fibrillation.

This sounds scary, and part of it is. But here is the part worth holding onto: the danger is temporary, and nearly everything that closes that window is something you and your doctor can actually do, starting with the urate-lowering treatment you may already have a prescription for. If you are in the middle of an attack, our guide to the first 12 hours of a flare covers what to do now. This piece explains what happens in your arteries afterward.

The Study That Found the Two-Month Danger Window

The research came from the University of Nottingham, using English medical records going back to 1997, and it was published in JAMA in 2022. The team, led by Edoardo Cipolletta and Abhishek Abhishek, did two analyses on the same question so that one would check the other.

The first compared over 10,000 people with gout who had a heart attack or stroke with a matched group of 52,000 who did not. People who had a heart attack or stroke were 1.93 times as likely to have had a flare in the previous 60 days, and 1.57 times as likely in days 61 to 120. After 180 days, there was no difference at all.

The second analysis is the one I find more convincing. It followed 1,421 people who had both a flare and a cardiovascular event and compared each person to themselves during ordinary periods. The rate of heart attacks and strokes ran at 2.49 per 1,000 person-days in the first 60 days after a flare versus 1.32 during baseline, an adjusted rate ratio of 1.89. Days 61 to 120 were still high at 1.64. When the event was fatal, the numbers were grimmer: people who died of a heart attack or stroke were close to 4.8 times as likely to have flared in the prior two months.

This was not a case of sick people being sick. The association held after the researchers excluded anyone with prior heart disease, and it showed up for heart attacks and strokes separately. Two other groups have since replicated it in different ways: a Western Australian linked-data study found a 1.7-fold rise in major cardiovascular events in the 30 days after a hospital admission for acute gout, and a 2025 analysis of people newly diagnosed with gout found a 1.55-fold spike in the first month, even in people early in their disease.

Why Would a Toe Flare Affect Your Heart?

Think of a flare as a fire alarm. Urate crystals shed from a deposit, and immune cells in the joint recognize them and release interleukin-1 beta, an inflammatory signal often shortened to IL-1β. That alarm does not stay inside the joint. Inflammatory markers rise in the bloodstream, and similar spikes after flu, pneumonia, and other short inflammatory illnesses are already tied to heart attacks in the weeks that follow.

The probable chain runs through your artery walls. Inflammation makes the lining of blood vessels work less well, and inside existing cholesterol plaques, activated immune cells release enzymes that chew at the fibrous cap holding the plaque in place. A thin cap can rupture. When that happens, a clot forms on the spot, and if it blocks a coronary artery you get a heart attack; if it blocks an artery in or leading to the brain, you get a stroke. Urate itself may add to this, since it can raise oxidative stress, platelet stickiness, and a clot-promoting signal called thromboxane, but the flare data point to the acute inflammation as the main short-term driver.

One honest caveat: these are observational records, not a trial in which flares were assigned to people, so they show a strong temporal association rather than proof that every flare directly causes an event. Researchers adjust hard for blood pressure, diabetes, kidney disease, medications, smoking, and weight, and the self-controlled design subtracts out each person’s fixed risk, but some residual confounding can never be ruled out. What the data support is practical rather than academic: treat the months after a flare as a period to pay attention.

It Is Not Only Heart Attacks and Strokes

The same Nottingham group ran two more self-controlled case series, and both surfaced short windows in the same spot.

Venous thromboembolism, meaning a deep-vein clot or a clot that travels to the lungs, ran 2.31 times the baseline rate in the first 30 days after a flare and 1.83 times across the full 90-day exposed window, published in Arthritis & Rheumatology in 2023. The absolute excess is modest, which matters, but a leg flare stacks the deck in two ways at once: inflammation makes blood clot more readily, and pain keeps you off the foot, so blood pools in the leg veins.

The More Flares You Have, the Heavier the Long-Term Toll

The short window is one thing. A 2026 study in Rheumatology asked a different question: does flare frequency add up over years? Researchers used the TriNetX network to follow 44,705 adults after their first treated flare, grouping them by how many flares hit in year one.

The dose-response was clear. People with four to six flares a year had a 1.24-fold higher risk of major cardiovascular events over seven years, and people with seven or more had a 1.45-fold risk. By year seven, 18.6 percent of the high-flare group had an event versus 12.9 percent of the low-flare group. Heart failure showed up earliest and most consistently, while stroke and heart attacks concentrated in the highest-flare group. The practical threshold the authors suggested is simple: more than three treated flares a year is a flag for closer cardiovascular review. It tracks closely with the American College of Rheumatology rule that two or more flares a year is already a reason to start urate-lowering treatment.

What Actually Closes the Window

Two interventions have the best evidence, and both run through a doctor’s office rather than a supplement shelf.

Treat to a urate target. A 2026 emulated target trial in JAMA Internal Medicine, again led by Cipolletta, followed 109,504 people newly started on urate-lowering therapy. Those whose serum urate fell below 6 mg/dL within 12 months had a 0.91-fold risk of a major cardiovascular event over five years, about a 9 percent relative reduction, with a 1 percent absolute difference in five-year event-free survival. People who hit the stricter target of under 5 mg/dL saw a larger reduction at a hazard ratio of 0.77. The mechanism is partly direct and partly plain: below the saturation point, crystals slowly dissolve, flares thin out, and the inflammatory spikes that open these windows stop happening. This is also why sticking with the pill matters; stopping allopurinol when the toe feels fine just lets the deposits rebuild.

Take flare prophylaxis seriously, especially colchicine. Starting urate-lowering therapy can itself trigger flares for the first months, as crystals loosen, which is why guidelines pair it with low-dose colchicine (brand name Colcrys in the U.S.), typically 0.6 mg once or twice daily, when kidneys and other medicines allow. A new-user cohort of nearly 100,000 people starting urate-lowering therapy, published in The Lancet Rheumatology in 2024, found that colchicine prophylaxis cut cardiovascular events in the following 180 days to a weighted hazard ratio of 0.82, with 28.8 events per 1,000 person-years versus 35.3 without prophylaxis. Low-dose colchicine also has its own cardiovascular track record: the COLCOT trial found 0.5 mg daily after a heart attack reduced further cardiovascular events by about 23 percent, and LoDoCo2 showed a similar effect in stable coronary disease.

Two cautions with colchicine. It is not interchangeable with a green light to self-medicate: the dose must be cut in significant kidney disease and it interacts dangerously with clarithromycin and some other strong CYP3A4 inhibitors, a combination tied to fatal toxicity, which we covered in our piece on the colchicine and clarithromycin interaction. And not every study has shown a heart benefit; a 2026 Korean nationwide cohort found no significant difference between colchicine and NSAID users who also had type 2 diabetes. The strongest signal sits with prophylaxis during urate-lowering initiation and with secondary prevention in known heart disease.

NSAIDs Deserve a Hard Look During This Window

This is the uncomfortable part. Nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen (Advil, Motrin) and naproxen (Aleve), knock down flare pain well, but they raise blood pressure, interfere with kidney function, and can worsen heart failure. The Nottingham data linked NSAID use with higher cardiovascular event rates than colchicine, and the current study summaries flag starting an NSAID as an added risk in the very window the flare already opened.

That does not mean one course is forbidden, and a short, carefully chosen NSAID remains a guideline-supported flare option for many people. It means the choice should match the person. If you carry a history of heart disease, uncontrolled blood pressure, heart failure, or kidney disease, ask specifically about colchicine or a corticosteroid course instead of defaulting to the familiar bottle in the cabinet. We compared the medication options in our article on what common medicines do to uric acid, and the rebound pattern after steroid courses is worth knowing before you choose, covered in our piece on the prednisone rebound.

What to Do in the Months After a Flare

You cannot will your arteries calm, but a short checklist covers most of what the evidence supports:

• Keep taking urate-lowering medicine through the flare and after, unless your prescriber says otherwise, and get re-tested until serum urate is reliably under 6 mg/dL.
• Ask about colchicine prophylaxis when starting or escalating urate-lowering therapy, and disclose every medicine you take so interactions and kidney dosing get checked.
• Do not ignore the classic warning symptoms in the weeks after a flare: chest pressure, sudden shortness of breath, one-sided weakness or numbness, trouble speaking, a fast or irregular heartbeat, or one-sided leg swelling with calf pain. These call for emergency help, not a wait-and-see morning.
• Move as soon as the joint tolerates it. Short walks cut the stasis part of clot risk, and gradual weight loss addresses the background risk that drives both gout and heart disease.
• Use the flare as a prompt to fix the slow-moving numbers, blood pressure, cholesterol, diabetes, and smoking, which set the baseline the inflammatory spikes land on.

The framing I would leave you with is this. A flare is not just a signal that your toe hurt for a week. It is a two-month reminder that the same inflammation burning in the joint can reach the heart and brain. Lowering urate to target and preventing the next flare are the same moves that take the cardiovascular danger off the table.

Frequently Asked Questions

How long does the raised heart attack risk last after a gout flare?

The clearest elevation runs about 60 days, with an adjusted rate ratio of 1.89 in the self-controlled analysis. Risk stays somewhat elevated through roughly 120 days and returns to baseline by 180 days. Blood clot and irregular-rhythm risks follow a similar short window, concentrated in the first 30 to 60 days.

Does lowering my uric acid actually protect my heart?

The best current evidence says it likely does. In a 2026 emulated target trial of 109,504 people, reaching a serum urate under 6 mg/dL within 12 months was associated with a 9 percent relative reduction in five-year major cardiovascular events, and reaching under 5 mg/dL with a 23 percent reduction. These are observational comparisons rather than a randomized trial, so certainty is moderate rather than absolute.

Should I take colchicine instead of ibuprofen for a flare?

For many people, especially anyone with high blood pressure, heart disease, heart failure, or kidney problems, low-dose colchicine is the safer first choice and it is a guideline-supported option. But the dose depends on kidney function, it has serious interactions with clarithromycin and similar drugs, and the decision belongs with whoever prescribes it. Do not swap medicines on your own.

What symptoms after a flare should send me to the emergency room?

Chest pressure or pain, sudden shortness of breath, fainting, a new fast or irregular heartbeat, one-sided weakness or facial droop, trouble speaking or sudden vision changes, and one-sided leg swelling with calf pain or breathlessness can each signal a heart attack, stroke, arrhythmia, or blood clot. In the weeks after a flare, take those symptoms seriously immediately rather than waiting them out.

I have one flare every few years. Does this apply to me?

The short-window data apply to flares generally, but absolute risk scales with age, existing cardiovascular risk, and flare burden. What the 2026 frequency study adds is that four or more flares a year marks a notably higher long-term risk, and guidelines already recommend urate-lowering therapy at two or more flares a year. Even infrequent flares are worth a conversation about your blood pressure, kidneys, and urate target.

Reviewed by the GoutSavvy Editorial Team